Conferences on Antiviral Research present a wealth of new information on novel drug development and the 21st annual meeting, held in Montreal between 13-17 April 2008, was no exception.

In her lab, Mary McCourt is busy developing a next-generation anti-viral therapy while training – and working alongside – the ...

Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: ...

The company has also secured a Department of Defense contract worth up to $34 million for the development of its antiviral drug, TNX-4200, in collaboration with X-Chem, Inc. Noble Capital analysts ...

In this review, we discuss the HCV life cycle in relation to current and future targets of antiviral drug development. The authors have no relevant affiliations or financial involvement with any ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Yesterday, SIGA Technologies, makers of the antiviral drug TPOXX (tecovirimat), announced that it has received $13 million in procurement orders for the drug, including two new international ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

This significant breakthrough in antiviral drug development brings new hope to the treatment of RSV infections in children globally. RSV is one of the most causative viruses for acute respiratory ...